Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of <i>in vivo</i> CAR-T platforms.

Front Immunol · 2026 · PMC13139153 · PMID 42093990

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

a positive trendP = 0.057so close (0.05 < p ≤ 0.1)

The median OS was 16.8 months in the ivonescimab group and 14.0 months in the placebo group, with a positive trend (HR, 0.79; 95% CI, 0.61 to 1.01; P = 0.057) ( 25 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of &lt;i&gt;in vivo&lt;/i&gt; CAR-T platforms.

The sentences

Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of <i>in vivo</i> CAR-T platforms.